RxDoctor Payments Data

Linda Ellard, APRN

Nurse Practitioner · Tulsa, OKNPI 1265948269

Payments from drug & device makers

$1,744in general payments, 2019–2025

Across 70 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$417
  • Collegium Pharmaceutical, Inc.$316
  • Averitas Pharma Inc.$305
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$257
  • Medtronic$183
  • Scilex Pharmaceuticals Inc.$153
  • plus $113 from 5 others

What the payments were for

  • Food & beverage$1,744100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,744 in reported general payments places this provider in the 85th percentile of 824 nurse practitioner providers in Oklahoma.

See all nurse practitioner providers in Oklahoma

Medicare billing

Part B allowed, 2024
$222,650
Medicare patients
159
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl359$57,539
BelbucaBuprenorphine Hcl36$27,991
Buprenorphine62$16,893
LinzessLinaclotide27$14,459
ZubsolvBuprenorphine Hcl/Naloxone Hcl16$12,936
Buprenorphine Hcl174$10,166
Emgality PenGalcanezumab-Gnlm11$7,642
Chlorzoxazone14$5,278
Lidocaine22$4,666
Naloxone Hcl44$2,880
Pregabalin137$2,556
Gabapentin194$2,291
Tizanidine Hcl143$1,416
Cyclobenzaprine Hcl131$1,382
Diclofenac Sodium28$1,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$316$27,99136 claims
AbbVieLinzess$417$14,45927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 824 nurse practitioner providers in Oklahoma.

Other nurse practitioner in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →